Familial breast cancer: Clinical response to induction chemotherapy or radiotherapy related to brca1/2 mutations status

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 32, Issue 2, 2009, Pages 127-131

  Fourquet, Alain ^a,b   Stoppa Lyonnet, Dominique ^a   Kirova, Youlia M ^a   Sigal Zafrani, Brigitte ^a   Asselain, Bernard ^b  

^a Department of Radiation Oncology ^*

^b INSTITUT CURIE   (France)

Author keywords

BRCA1; BRCA2; Breast cancer; Chemotherapy; Familial cancers; Neoadjuvant treatment; Radiation therapy

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CHEMOSENSITIVITY; CLINICAL FEATURE; CONTROLLED STUDY; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SCREENING; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; ORGAN PRESERVATION; OVARY CANCER; RADIATION RESPONSE; RADIOSENSITIVITY; TREATMENT RESPONSE; TUMOR VOLUME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS REGULATORY PROTEINS; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; GERM-LINE MUTATION; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 67749097987     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31817f9e1c     Document Type: Article

References (34)

1. Scholl S, Fourquet A, Asselain B, et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer. 1994;30A:645-652.
2. Broet P, Scholl S, de la Rochefordiere A, et al. Short and long-term effects on survival in breast cancer patients treated by primary chemotherapy: an updated analysis of a randomized trial. Breast Cancer Res Treat. 1999;58: 151-156.
3. Easton DF, Bishop DT, Ford D, et al. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. Am J Hum Genet. 1993;52:678-701.
4. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998;62:676-689.
5. Eisinger F, Stoppa-Lyonnet D, Longy M, et al. Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res. 1996;56:471-474.
6. Lakhani SR, Jacquemier J, Sloane JP, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst. 1998;90:1138-1145.
7. Stoppa-Lyonnet D, Ansquer Y, Dreyfus H, et al. Familial invasive breast cancers: worse outcome related to BRCA1 mutations. J Clin Oncol. 2000; 18:4053-4059.
8. Robson M, Levin D, Federici M, et al. Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. J Natl Cancer Inst. 1999;91:2112-2117.
9. Foulkes WD, Chappuis PO, Wong N, et al. Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome. Ann Oncol. 2000; 11:307-313.
10. Venkitaraman A. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 2002;108:171-182.
11. Stoppa-Lyonnet D, Laurent-Puig P, Essioux L, et al. BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Institut Curie Breast Cancer Group. Am J Hum Genet. 1997;60:1021-1030.
12. Claus EB, Risch N, Thompson WD. Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet. 1991;48:232-242.
13. Campana F, Kirova YM, Rosenwald JC, et al. Breast radiotherapy in the lateral decubitus position-a technique to prevent lung and heart irradiation. Int J Radiat Oncol Biol Phys. 2005;61:1348-1354.
14. Kirova Y, Servois V, Campana F, et al. CT-scan based localization of the internal mammary chain and supra clavicular nodes for breast cancer radiation therapy planning. Radiother Oncol. 2006;79:310-315.
15. Wagner T, Stoppa-Lyonnet D, Fleischmann E, et al. Denaturing high-performance liquid chromatography detects reliably BRCA1 and BRCA2 mutations. Genomics. 1999;62:369-376.
16. Gad S, Aurias A, Puget N, et al. Color bar coding the BRCA1 gene on combed DNA: A useful strategy for detecting large gene rearrangements. Genes Chromosomes Cancer. 2001;31:75-84.
17. Casilli F, Di Rocco ZC, Gad S, et al. Rapid detection of novel BRCA1 rearrangements in high-risk breast-ovarian cancer families using multiplex PCR of short fluorescent fragments. Hum Mutat. 2002;20:218-226.
18. Smith IE, Lipton L. Preoperative/neoadjuvant medical therapy for early breast cancer. Lancet Oncol. 2001;2:561-570.
19. Chappuis PO, Goffin J, Wong N, et al. A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancers. J Med Genet. 2002;39: 608-610.
20. Delaloge S, Pelissier P, Kloos I, et al. BRCA1-linked breast cancer is highly more chemosensitive than its BRCA2-linked or sporadic counterparts. In: Abstract of 27th Congress of the ESMO, 2002.
21. Brekelmans CT, Tilanus-Linthorst MM, Seynaeve C, et al. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer. 2007;43:867-876.
22. Rozan S, Vincent-Salomon A, Zafrani B, et al. No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int J Cancer. 1998;79:27-33.
23. Freneaux P, Stoppa-Lyonnet D, Mouret E, et al. Low expression of bcl-2 in BRCA1-associated breast cancers. Br J Cancer. 2000;83:1318-1322.
24. Hedenfalk I, Duggan D, Chen Y, et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med. 2001;344:539-548.
25. Gudmundsdottir K, Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene. 2006;25:5864-5874.
26. Scully R, Chen J, Ochs RL, et al. Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell. 1997;90:425-435.
27. Xu X, Weaver Z, Linke SP, et al. Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol Cell. 1999;3:389-395.
28. Brodie SG, Xu X, Qiao W, et al. Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice. Oncogene. 2000;20:7514-7523.
29. Robson ME, Chappuis PO, Satagopan J, et al. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/2 mutation status and administration of adjuvant treatment. Breast Cancer Res. 2004;6:R8-R17.
30. Rennert G, Bisland-Naggan S, Barnett-Griness O, et al. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med. 2007;357:115-123.
31. Petit T, Wilt M, Rodier J, et al. Are BRCA1 mutations a predictive factor for anthracycline-based neoadjuvant chemotherapy response in triple negative breast cancers? [2007 ASCO Annual Meeting Proceedings]. J Clin Oncol.2007;25(suppl):580.
32. Byrski T, Gronwald J, Huzarski T, et al. Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res Treat. 2008;108:289-296.
33. Kirova Y, Stoppa-Lyonnet D, Savignoni A, et al. Risk of breast recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. Eur J Cancer. 2005;41:2304-2311.
34. Pierce LJ, Levin AM, Rebbeck TR, et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol. 2006;24:2437-2443.